FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
Published . Updated .
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Directly affected
- GRAL Grail
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Source: MarketWatch
How far Acadia Healthcare (ACHC) has moved since 23 Sep 2026
Since the first closing price after “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.,” Acadia Healthcare (ACHC) is +8.55%. The S&P 500 fund (SPY) is -0.09% over the same days, a +8.64% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 23 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 6 days after publication, inside 30 days. The filing is listed beside the story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 12 days before publication, inside 30 days. The filing is listed beside the story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 51 days before publication, inside 60 days. The filing is listed beside the story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow..” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.,” the 23 Sep 2026 this story story.
The link for Acadia Healthcare (ACHC) is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.